Metronidazole pessaries compared with placebo in the treatment of bacterial vaginosis.
In a randomized, double-blind clinical trial from general practice, 500 mg metronidazole pessaries applied once daily for seven days were compared with placebo in the treatment of bacterial vaginosis. Seventy-five women completed the study. At the follow-up visit immediately after completion of treatment, none of the patients on metronidazole fulfilled the criteria for bacterial vaginosis, compared with 12 (35%) in the placebo group (p less than 0.001). Nine (22%) of the patients treated with metronidazole harboured Gardnerella vaginalis after treatments, compared with 31 (91%) in the placebo group (p less than 0.001). Symptoms had improved or disappeared in 33 (80%) on metronidazole, and in 18 (53%) on placebo therapy (p less than 0.05). Four weeks after the follow-up visit, symptoms were reported by 28% in the metronidazole group and by 44% in the placebo group (p greater than 0.05). Metronidazole pessaries are effective in the treatment of bacterial vaginosis.
Bro
F
F
Institute of General Practice, University of Aarhus, Denmark.
D000328:Adult; D002181:Candidiasis, Vulvovaginal / Q000188:drug therapy; D004311:Double-Blind Method; D005194:Family Practice; D005260:Female; D006194:Gardnerella vaginalis / Q000302:isolation & purification; D006192:Haemophilus Infections / Q000188:drug therapy* / Q000382:microbiology; D006801:Humans; D008795:Metronidazole / Q000008:administration & dosage* / Q000627:therapeutic use; D010570:Pessaries; D010919:Placebos; D014627:Vaginitis / Q000175:diagnosis / Q000188:drug therapy*
D010919:Placebos; D008795:Metronidazole